承認された医薬品
規制当局が、少なくとも一つの国で少なくとも一つの用途について認可しています。認可された範囲外の用途について何かを示すものではありません。
このページは作成途中です
The wiki has this compound's identity from the My-Pepts library, its standing, and what PubMed holds for it. The article, with its studies read and cited, is not written yet. Until it is, the counts below say how much research exists, not what it found.
作用の強さ
どこまで到達したか
どの医薬品も同じ段階を上っていきます。ほとんどの化合物は頂点に届かず、どの段階にあるかによって、その主張がどこまで支えられるかが分かります。
- 承認された医薬品: Dulaglutide
規制当局が試験を審査し、特定の用途に対して承認したものです。
- 第3相
数千人を含むこともある大規模なランダム化試験で、プラセボまたは標準治療と比較します。
- 第2相
病態のある人を対象に、用量と効果の関係を測定する中規模の試験です。
- 第1相および初期のヒト試験
人を対象とした最初の試験で、安全性と体内での扱われ方を調べます。
- 細胞および動物
実験室および動物での研究です。動物での結果は人での結果ではありません。
- 540
- PubMed上の論文
- 334
- うち人を対象としたもの
- 115
- ランダム化試験
- 42
- 総説
件数は、どれだけ公表されたかを示すもので、何が分かったかを示すものではありません。PubMed上の件数: 2026-11-16
取り扱いと溶解
粉末から測定された試料まで
The same four steps for any lyophilized vial. Laboratory handling, not use in a person.
1. バイアルのラベルを読む
ラベルには、バイアル内のペプチドの質量がミリグラム単位で記載されています。この数値が、すべての計算の出発点です。
2. 希釈液を加える
計量した量の希釈液を、ガラス壁を伝わせてゆっくり加えます。やさしく回し混ぜてください。振るとペプチドを損なうおそれがあります。
3. 濃度を求める
Concentration is mass divided by volume: 10 mg in 2 mL is 5 mg per mL.
4. 試料の量を測る
必要な体積は、必要な質量を濃度で割ったものです。U-100注射器では、1 mLが100単位です。
以下の計算機で計算を行い、その過程を表示します。
As powder
General practice for lyophilized peptides: keep the sealed vial frozen or refrigerated, dry and away from light, and follow the supplier's certificate of analysis.
In solution
Once in solution a peptide is kept refrigerated and used within the period the supplier states. A vial drawn from more than once needs a preserved diluent such as bacteriostatic water.
This is general practice for lyophilized peptides, not data on Dulaglutide itself. The batch's certificate of analysis and the supplier's sheet are the facts to go by. More on storage
Reconstitution calculator
Opens on vial sizes common for research peptides. Change any number. How the arithmetic works
Draw to
10 units
0.1 mL on a U-100 syringe
- Concentration
- 2.5 mg/mL
- Each unit holds
- 25 mcg
- Samples in the vial
- 20
- Sample
- 250 mcg
5 mg in 2 mL is 2.5 mg/mL. 250 mcg of that is 0.1 mL, which reads as 10 units. This is arithmetic for a vial of Dulaglutide; no amount here is a recommendation.
Dulaglutide: PubMedで
What PubMed held for Dulaglutide on November 16, 2026. A count says how much a compound has been studied, not what the studies found: how to read these numbers.
- 540
- papers
- 334
- in humans
- 125
- clinical trials
- 115
- randomized trials
Most relevant on PubMed
Listed by PubMed's own relevance ranking, trials and reviews first. The wiki has not read these into the article unless they are also among its sources.
- Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial
Randomized trialGerstein HC, Colhoun HM, Dagenais GR, et al. Lancet (London, England), 2019. PMID 31189511
- Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes
TrialNicholls SJ, Pavo I, Bhatt DL, et al. The New England journal of medicine, 2025. PMID 41406444
- Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial
Randomized trialPratley RE, Aroda VR, Lingvay I, et al. The lancet. Diabetes & endocrinology, 2018. PMID 29397376
- Comparative effectiveness of semaglutide versus liraglutide, dulaglutide or tirzepatide: a systematic review and meta-analysis
ReviewKarimi MA, Gholami Chahkand MS, Dadkhah PA, et al. Frontiers in pharmacology, 2025. PMID 40444045
- Cardiorenal Outcomes With Tirzepatide Compared With Dulaglutide in Patients With Diabetes and Cardiovascular Disease: A Post Hoc Analysis of the SURPASS-CVOT Randomized Clinical Trial
Randomized trialNissen SE, Wolski K, D'Alessio D, et al. JAMA cardiology, 2026. PMID 41903177
- Comparative Meta-Analysis of Retatrutide Versus Placebo and Dulaglutide for Weight Loss and Diabetes Management: Insights From Clinical Trials
Meta-analysisAyesh H, Ayesh S, Niswender K American journal of therapeutics, 2024. PMID 38976545
- Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: SURPASS-CVOT design and baseline characteristics
TrialNicholls SJ, Bhatt DL, Buse JB, et al. American heart journal, 2024. PMID 37758044
- Dulaglutide
Review, 2006. PMID 30000038
Search used: ("Dulaglutide"[ti]). Run it on PubMed
研究リンク
- PubMed (opens in a new tab)Every indexed paper, newest first
- ClinicalTrials.gov (opens in a new tab)Registered trials and their status
- Europe PMC (opens in a new tab)Full text where it is open access
- Google Scholar (opens in a new tab)Papers, preprints and who cites them
- PubChem (opens in a new tab)Structure, identifiers and properties
- YouTube (opens in a new tab)Talks and lectures. Check who is speaking
These open a search for Dulaglutide on each site. The wiki has not reviewed what they return: a video or a preprint is not a peer-reviewed result, and none of it is medical advice.